CGRP mAb therapies show good effectiveness post-approval in chronic migraine

Results presented at AHS 2020 suggest that, in a real-world setting, calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) therapies show the effectiveness that might be expected from clinical trial results. However, when patients need to switch from one CGRP mAb therapy to another, the results are often disappointing.

Want to read more?

Log in or sign up to access all Neurodiem content.

Already have an account? Log In

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.